GLP-1 Navigator
Coverage Intelligence
Coverage guide

What insurance covers Zepbound in 2026

Zepbound coverage varies more than almost any other branded drug — by insurer, by plan, by employer, and by indication. Here's the practical breakdown by plan type, plus what to do when coverage is denied.

Key takeaways
  • Most commercial plans cover Zepbound for OSA; coverage for obesity is mixed
  • Original Medicare excludes weight-loss drugs by statute, but may cover for OSA
  • About 15 state Medicaid programs cover Zepbound for obesity
  • Self-funded employer plans can include or exclude weight-loss coverage at will
  • LillyDirect cash-pay vials start at $349/month

Commercial insurance (BCBS, Aetna, Cigna, UHC, etc.)

Most major commercial insurers cover Zepbound when prior authorization criteria are met — typically BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (T2D, HTN, dyslipidemia, OSA). The December 2024 OSA approval expanded coverage further: many plans that previously excluded Zepbound as a weight-loss drug now cover it under the OSA label.

Step therapy is common. Plans often require documented prior trials of phentermine, orlistat, or a structured lifestyle program before approving Zepbound.

Medicare

Medicare Part D is statutorily prohibited from covering drugs used for weight loss alone. Zepbound for obesity is therefore not covered. However, Zepbound's 2024 OSA approval created a non-weight-loss covered indication — some Part D plans have added Zepbound to their formulary for OSA. For diabetes, Mounjaro (the same molecule, tirzepatide) is widely covered by Part D.

Medicaid

Medicaid coverage of GLP-1s for obesity is decided state-by-state. As of 2026, approximately 15 states cover Zepbound for obesity, often with strict BMI and comorbidity criteria. Most state programs cover Mounjaro for type 2 diabetes. Check your state Medicaid agency's preferred drug list (PDL) for current rules.

Employer-sponsored plans (self-funded)

Roughly half of large U.S. employers exclude anti-obesity medications from their pharmacy benefit. Self-funded employers (most companies with 1,000+ employees) make this choice independently of the insurer named on your card. If your card says 'Aetna' but your employer self-funds, Aetna's published formulary may not match your actual coverage — call the number on your card to confirm.

Paying out of pocket

LillyDirect (Lilly's direct-to-patient pharmacy) sells single-dose Zepbound vials starting at $349/month for the 2.5 mg dose and $499/month for higher doses. This is the lowest legitimate cash price.

The Zepbound Savings Card lowers commercially-insured copays to as low as $25/month and reduces the list price by about $650/month for uninsured patients.

Compounded tirzepatide is no longer broadly available — the FDA ended the official shortage in late 2024, restricting compounding pharmacies.

Frequently asked questions

Get a personalized coverage assessment

Answer a few clinical questions and receive a personalized approval-likelihood score with a prior-authorization checklist tailored to your plan.

Educational guidance only — not medical or legal advice.